研究目的
Investigating the use of plasmonic metasurface for label-free detection of human tumor markers to benefit clinical examination.
研究成果
The plasmonic metasurface of gold nanobump array achieved by an optimized nanofabrication process provides many advantages for tumor maker detection in human serum. The flexible lightweight plasmonic metasurfaces based on low-cost manufacture and simple optical configuration demonstrate a promising potential for future portable medical devices/systems in point-of-care diagnosis and mobile healthcare.
研究不足
The study focuses on the detection of carcinoembryonic antigen (CEA) and may not cover other tumor markers. The fabrication process, while optimized, may still require further refinement for mass production.
1:Experimental Design and Method Selection:
The study adopts nanoimprint and plasma etching to optimize the nanofabrication for low-cost flexible plasmonic metasurface sensors with gold nanobump arrays.
2:Sample Selection and Data Sources:
Human serum samples are collected from the First Affiliated Hospital of Xiamen University.
3:List of Experimental Equipment and Materials:
Includes polycarbonate slices, self-assembly reagent 11-Mercaptoundecanoic acid (MUA), phosphate buffer saline (PBS), 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), Bovine serum albumin (BSA), CEA and its antibody anti-CEA.
4:Experimental Procedures and Operational Workflow:
Fabrication of plasmonic metasurfaces involves nanoimprint, etching and metal evaporation. Bio-functionalization includes thiolate modification and covalent immobilization of anti-CEA.
5:Data Analysis Methods:
Optical measurement and simulation based on the finite element method.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容